Related by context. All words. (Click for frequent words.) 74 mTSS 73 ADAS cog 73 Crohn Disease Activity 72 Index CDAI 71 Montgomery Asberg Depression 71 Health Assessment Questionnaire 71 PANSS 71 MADRS score 70 DAS# [002] 70 Alzheimer Disease Assessment 70 ADAS Cog 69 lumbar spine BMD 69 YMRS 69 CDAI 69 IBDQ 69 MADRS 69 NIHSS 68 WOMAC pain 68 NIH CPSI 68 HOMA IR 68 EDSS score 68 Brief Psychiatric 68 PANSS total 67 Expanded Disability Status 67 CDAI score 67 Rating Scale MADRS 67 PASI scores 67 clinically meaningful improvement 67 MMSE score 67 Scale EDSS 67 Negative Syndrome 67 ADCS CGIC 67 Physical Component 67 liver histology 67 SGRQ 67 HRQL 67 ADCS ADL 67 plus MTX 67 HDRS 67 PCWP 66 UPDRS 66 QTcF 66 Unified Parkinson Disease 66 virologic response 66 IPSS 66 platelet reactivity 66 DAS# scores 66 subscale scores 65 ACR# response 65 baseline HbA1c 65 CI -#.# 65 CCyR 65 6MWD 65 Psoriasis Area 65 Hb A1C 65 CNS LS 65 subscore 65 -#.# mg dL [002] 65 Visual Analogue Scale VAS 65 prospectively stratified 65 IRLS 65 Y BOCS 65 Montgomery Åsberg Depression 64 ANCOVA 64 serologically active patients 64 PSADT 64 BMI z 64 Disease Activity 64 PANSS scores 64 Global Impression CGI 64 metabolic parameters 64 EQ 5D 64 Neuropsychiatric Inventory 64 Primary endpoints 64 NIHSS score 64 DAS# CRP 64 Visual Analog Scale 64 HbA 1c levels 64 capillary density 64 -#.# mg dL [001] 64 Secondary efficacy endpoints 64 virological response 64 serum aminotransferase levels 64 Secondary endpoints included 64 carotid IMT 64 p = .# [002] 64 WOMAC 64 cardiac autonomic 63 intima media thickness 63 WOMAC TM 63 Scale cognitive subscale 63 CPAP adherence 63 demonstrated clinically meaningful 63 Platelet counts 63 DLQI 63 Scale PANSS 63 Fibromyalgia Impact Questionnaire 63 HAMD 63 corticosteroid dose 63 SELENA SLEDAI 63 Pharmacokinetic parameters 63 morphometric vertebral fractures 63 Symptom severity 63 HbA1C levels 63 FACIT Fatigue 63 sUA 63 Score IPSS 63 methacholine challenge 63 hemoglobin A1c levels 63 cognitive affective 63 leukocyte count 63 creatinine clearance 63 methotrexate monotherapy 63 mRS 63 International Prostate Symptom 63 moderate renal impairment 63 radiographic progression 63 annualized relapse 63 CIBIC plus 63 neurocognitive function 63 Secondary endpoints include 63 serum HBV DNA 63 fasting plasma glucose FPG 63 hip BMD 63 glycosylated hemoglobin HbA1c 62 INVEGA ® 62 bortezomib refractory 62 symptom severity 62 SSRI SNRI 62 progression TTP 62 CORE OM 62 NNT = 62 placebo p 62 HbA 1c 62 ADHD RS 62 atheroma volume 62 subscales 62 hematologic parameters 62 NYHA functional class 62 Secondary endpoints 62 retinal thickness 62 QTc intervals 62 left ventricular diastolic 62 Ocular Surface Disease 62 LVEF 62 endometrial thickness 62 QoL 62 clinically meaningful improvements 62 glycated hemoglobin levels 62 trough FEV1 62 Baseline characteristics 62 albumin excretion rate 62 Visual acuity 62 euthymic patients 62 IRLS score 62 virologic responses 62 fasting insulin 62 Cardiorespiratory fitness 62 UPDRS motor 62 SCr 62 baseline A1C 62 CR nPR 62 posttreatment 62 Score TOS 62 Ishak fibrosis score 62 Non inferiority 62 HBeAg seroconversion 62 DAS# remission 62 spirometric 62 prospectively defined 62 Severity Index PASI 62 achieved statistical significance 62 ACR# [002] 62 EDSS scores 61 timepoints 61 baseline FEV 61 Global Impression 61 MoxDuo TM IR 61 extrapyramidal symptoms 61 echocardiographic parameters 61 HER2 expression 61 Score DAS# 61 plus methotrexate 61 VKORC1 61 affective psychosis 61 CrCl 61 placebo p = 61 alanine aminotransferase ALT 61 poststroke 61 pulmonary capillary wedge 61 estimated glomerular filtration 61 fasting plasma glucose 61 oxycodone CR 61 CIMZIA TM 61 RECIST Response Evaluation Criteria 61 SELENA SLEDAI score 61 multivariate Cox 61 preoperatively 61 -#.# log# 61 pulmonary exacerbations 61 Key secondary endpoints 61 glycosylated hemoglobin levels 61 P = .# 61 WOMAC scores 61 spontaneous bowel movements 61 log# copies mL 61 -#.# ± [002] 61 foveal thickness 61 secondary efficacy endpoint 61 ADHD Rating Scale 61 hsCRP levels 61 abdominal pain abdominal discomfort 61 serum phosphate 61 Scale EDSS score 61 pharmacodynamic parameters 61 Severity MSCS score 61 TNSS 61 tissue oxygenation 61 serum clusterin levels 61 MMSE scores 61 ACR# responses 61 baseline LDH 61 left ventricular systolic 61 glomerular filtration 61 UPDRS scores 61 serum phosphorous 61 glycated hemoglobin HbA1c 61 T2 lesions 61 HRQOL 61 State Examination MMSE 61 albumin excretion 61 serum urate 61 hematological parameters 61 neutrophil counts 61 ± SD 61 tipranavir r 61 #.#/#.# mmHg [001] 61 HbA1c levels 61 Timed Walk 61 gadolinium enhancing lesions 61 peak VO2 61 Capacity FVC 61 nasal symptom 61 serum potassium 60 Oswestry Disability Index 60 EDSS 60 Index CDAI score 60 CD4 CD8 60 symptomatic VTE 60 premorbid 60 Index HAQ DI 60 attain statistical significance 60 genotypic resistance 60 subscores 60 psychosocial variables 60 dactylitis 60 statistically significant p = 60 anemia hemoglobin 60 Inventory BPI 60 Erectile function 60 LS BMD 60 atherogenic dyslipidemia 60 haematologic 60 sustained virological response 60 Tasigna prolongs 60 postoperative mortality 60 IFN α 60 Kaplan Meier analysis 60 -#.# log# copies mL 60 AUA Symptom Score 60 BPH Symptom Score 60 logistic regression models 60 Dyspnea 60 % CI #.#-#.# [007] 60 CIMZIA ™ 60 Negative Symptoms 60 glucose homeostasis 60 APOE genotype 60 multivariable Cox 60 preintervention 60 mean ± SEM 60 macroalbuminuria 60 treat NNT 60 docetaxel pretreated 60 hemodynamic parameters 60 tapentadol ER 60 urine albumin 60 glomerular filtration rate 60 PSQI 60 MetS 60 ACR# ACR# 60 euthymic 60 ALSFRS R 60 plasma leptin 60 univariate 60 apnea hypopnea index 60 seropositive patients 60 HRQoL 60 HAM D# 60 mcg BID 60 tumor histology 60 PSA nadir 60 daytime somnolence 60 QTc 60 autonomic dysfunction 60 serum phosphate levels 60 Insulin sensitivity 60 certolizumab 60 amnestic mild cognitive impairment 60 Score DAS 60 Skin sterol 60 creatinine ratio 60 serum creatinine levels 60 achieved CCyR 60 sub maximal 60 Natalizumab 60 serum phosphorus 60 REMINYL ® 60 Logistic regression 60 baseline CD4 + 60 Charlson comorbidity index 60 CRp 60 MMSE 60 depressive symptom 60 erythrocyte sedimentation rate 60 Histologic 60 venlafaxine XR 60 Viral load 60 A1c levels 60 QRS duration 60 abacavir lamivudine 60 log# IU mL 60 Free Survival PFS 59 sd = 59 APACHE II 59 CSBMs 59 aMCI 59 8mg/kg 59 HAM D# scores 59 lactate dehydrogenase LDH 59 brachial artery flow 59 intravascular hemolysis 59 symptomatology 59 NPH insulin 59 HBeAg negative patients 59 Interrater reliability 59 tipranavir ritonavir 59 intraobserver 59 electrophysiologic 59 neurocognitive functioning 59 CNV lesion 59 complete cytogenetic response 59 p = #.# [002] 59 mg kg dose 59 univariate analyzes 59 dyssynchrony 59 conditional logistic regression 59 biochemical recurrence 59 urinary N telopeptide 59 femoral neck BMD 59 postintervention 59 achieved ACR# 59 Kaplan Meier survival 59 preoperative PSA 59 ± SEM 59 postoperative pulmonary 59 enthesitis 59 undetectable HCV RNA 59 hemoglobin Hb 59 lymphocytosis 59 Mental Component 59 confidence intervals CIs 59 Rating Scale UPDRS 59 sustained virologic response 59 antipsychotic efficacy 59 prespecified 59 biopsy Gleason 59 HbA1c 59 serum urate levels 59 ALS Functional 59 Pain Intensity 59 STRIDE PD 59 virologic failure 59 convergent validity 59 HIV RNA 59 alanine aminotransferase 59 paliperidone ER 59 intact parathyroid hormone 59 Rate ORR 59 aminotransferase levels 59 plasma creatinine 59 ICD therapy 59 desvenlafaxine succinate 59 T2DM 59 troponin T 59 mg TID 59 hepatic fibrosis 59 corrected QT interval 59 Subgroup analysis 59 Hamilton Anxiety Scale 59 lymphocyte count 59 CIMZIA TM certolizumab pegol 59 SBM frequency 59 erection hardness 59 postoperative AF 59 EORTC QLQ C# 59 Neuropsychiatric Inventory NPI 59 CHADS2 59 endoscopic remission 59 Ashworth Scale 59 haemodynamic 59 confirmed CCyR 59 insulin detemir 59 periprocedural 59 lactate dehydrogenase 59 hemoglobin A1c HbA1c 59 amisulpride 59 antioxidant supplementation 59 bronchial hyperresponsiveness 59 timepoint 59 pCR 59 Brief Pain 59 pulmonary arterial 59 μmol L 59 exploratory endpoints 59 response CCyR 59 bivariate 59 Mean Symptom Complex 59 mL/min/#.# m 2 59 mineral density BMD 59 adalimumab 59 % CI #.#-#.# [003] 59 Descriptive statistics 59 nonfasting triglyceride levels 59 baseline CD4 59 kidney allograft 59 angiographic outcomes 59 ratio ICER 59 MS DRGs 59 perioperative complications 59 activated partial thromboplastin 59 serum PTH 59 PsA 58 aminotransferases 58 glycated hemoglobin 58 MDRD 58 p = #.# [003] 58 psychiatric comorbidity 58 oral anticoagulation 58 Febrile neutropenia 58 CFQ R 58 IIEF 58 aMCI precursor 58 Geriatric Depression 58 non menstrual pelvic 58 lopinavir r arm 58 multiple linear regression 58 Ejection Fraction 58 depressive symptomatology 58 lipid parameters 58 somatostatin analog 58 mucosal healing 58 hemoglobin concentration 58 unpaired t 58 Wechsler Adult 58 antibody titer 58 multivariable logistic regression 58 postprocedure 58 Postoperatively 58 overt nephropathy 58 HbA1C 58 Clinician Administered PTSD 58 PITX2 methylation 58 postdose 58 hemoglobin concentrations 58 hippocampal volume 58 subthreshold depression 58 viral kinetics 58 secondary endpoint 58 FEV1 58 interobserver 58 titrated glipizide 58 Main Outcome Measures 58 DAPT 58 dyslipidaemia 58 aspartate aminotransferase AST 58 ACTEMRA TM 58 Comorbidity 58 ETDRS 58 adenotonsillectomy 58 oral FTY# 58 blood Phe levels 58 RAPAFLO R 58 prespecified secondary 58 Mania Rating Scale 58 posttransplant 58 % Confidence Interval 58 oncologic outcomes 58 OGTT 58 interobserver reliability 58 serum creatinine 58 Cholinesterase Inhibitors 58 sweat chloride 58 interrater reliability 58 Physical Function 58 mg QD 58 octreotide LAR 58 visceral adiposity 58 tolterodine ER 58 antiretroviral naïve 58 myocardial reperfusion 58 serum sodium 58 aromatase inhibitor therapy 58 relapsed MM 58 mg BID dose 58 eGFR 58 logistic regression model 58 subclinical atherosclerosis 58 hepatic enzymes 58 inotropic 58 apolipoprotein B 58 #q# deletion syndrome 58 Solid Tumors criteria 58 CI #.#-#.# [001] 58 ejection fractions 58 eplerenone 58 IFN alfa 58 residual platelet reactivity 58 allele frequencies 58 Functional Outcomes 58 CYP#A# substrate 58 Hemoglobin A1c 58 hippocampal volumes 58 FDA defined valvulopathy 58 estimated GFR 58 Cronbach alpha 58 % CI #.#-#.# [006] 58 meta regression 58 fibrinolysis 58 undetectable HBV DNA 58 posttest 58 paricalcitol 58 4mg/kg 58 transcranial Doppler ultrasound 58 PSA kinetics 58 FOLPI 58 teriflunomide 58 multivariate regression analysis 58 multivariable analysis 58 placebo fluoxetine 58 Response Evaluation Criteria 58 HCV RNA 58 Scale Cognitive Subscale 58 baroreceptor reflex 58 ASIA Impairment 58 T2 lesion volume 58 univariate analysis 58 virologic 58 hemodynamic measurements 58 neurocognitive deficits 58 Status Scale EDSS 58 psychosocial functioning 58 covariate 58 intravenous cyclophosphamide 58 multivariate logistic regression 58 Forced Vital 58 nonoperative treatment 58 laboratory abnormalities 58 SSRI citalopram 58 oral antidiabetes 58 baroreflex 58 HIV tropism 58 microalbuminuria 58 airway hyperresponsiveness 58 nerve conduction velocity 58 tiotropium 58 Median PFS 58 F FDG PET 58 dyspnoea 58 CSBM 58 tolvaptan 58 SBMs 58 interquartile range 58 obstructive CAD 58 β blocker 58 psoriatic arthritis PsA 58 mean baseline A1C 58 chi squared 58 GERD symptom 58 creatinine levels 58 ACZ# 58 serum IGF 58 pramipexole 58 glycemia 57 neuroleptic 57 Uncontrolled hypertension 57 neurologic progression 57 System IPSS 57 XIENCE V PROMUS Stent 57 untreated psychosis 57 blood Phe 57 CLA supplementation 57 arterial oxygen saturation 57 SLE Responder Index 57 EuroSCORE 57 eNO 57 SVR# 57 acetabular dysplasia 57 mg BID 57 HSCT 57 LDL HDL 57 Cockcroft Gault 57 EBMT criteria 57 fructosamine 57 coagulation parameters 57 pharmacodynamic PD 57 rhGH 57 ACR Pedi 57 receiving golimumab 57 binary logistic regression 57 divalproex sodium 57 β blockers 57 Cystatin C 57 Rating Scale BPRS 57 Subgroup analyzes 57 mcg Albuferon 57 serum testosterone 57 complete cytogenetic 57 cerebrovascular events 57 mesalamine granules 57 receiving VICTRELIS 57 postoperative complication 57 TURBT 57 plasma renin activity 57 transaminase levels 57 primary aldosteronism 57 bezafibrate 57 hypoperfusion 57 CTEPH 57 IL 1ß 57 postdischarge 57 ANOVA 57 = #.#-#.# 57 rFSH 57 HER2 overexpression 57 serum concentrations 57 arterial thickening 57 UPDRS Part III 57 solifenacin 57 antiangiogenic therapy 57 vasopressor 57 comorbid anxiety 57 multivariable adjusted 57 SUVmax 57 methotrexate therapy 57 nonparametric 57 ug kg 57 baseline PASI 57 logistic regression analysis 57 systolic function 57 cortical atrophy 57 antidepressant efficacy 57 detectable HCV RNA 57 fibrosis progression 57 impaired endothelial 57 p = .# [001] 57 pyridostigmine 57 dose atorvastatin 57 mRCC 57 iPTH 57 GAMMAGARD 57 submaximal 57 antidepressant monotherapy 57 definite stent thrombosis 57 preoperative chemotherapy 57 LV ejection fraction 57 Hb levels 57 imatinib therapy 57 diabetes mellitus DM 57 glatiramer acetate 57 systolic dysfunction 57 conventional antipsychotics 57 creatinine clearance CrCl 57 HAM D 57 #mg/day [001] 57 SF #v# 57 oral antidiabetic medication 57 nicardipine 57 psychiatric comorbidities 57 confidence interval CI 57 tumor progression TTP 57 Teriflunomide 57 infliximab monotherapy 57 nondiabetic patients 57 conventional DMARDs 57 TWYNSTA 57 stratifying patients 57 pulmonary vascular 57 HbA 1C 57 parkinsonian symptoms 57 recurrent VTE 57 pharmacokinetic PK profile 57 Fasting glucose 57 clinically meaningful reductions 57 BENICAR HCT 57 IELT 57 % CI #.#-#.# [005] 57 covariance 57 Hb 57 salivary cortisol 57 covariance ANCOVA 57 Tumor Response 57 tic severity 57 NATRECOR R 57 adenoma recurrence 57 REYATAZ r arm 57 RYGB 57 aldosterone antagonist 57 dapagliflozin plus 57 splenectomized patients 57 cerebral oxygenation 57 budesonide pMDI 57 transaminase elevations 57 CsA 57 affective psychoses 57 myocardial viability 57 mineral density 57 multivariate analyzes 57 NIS LL 57 cEVR 57 median CD4 57 symptom exacerbation 57 elevated ALT 57 RLAI 57 TDF FTC 57 nonvertebral fractures 57 quetiapine 57 coronary revascularization procedures 57 cortical activation 57 serum cortisol 57 Multivariate logistic regression 57 left ventricular LV 57 Cystic Fibrosis Questionnaire Revised 57 cardiovascular calcification 57 hematologic toxicity 57 daunorubicin 57 triiodothyronine 57 BPRS 57 #.#/#.# mm Hg [003] 57 MELD score 57 Kaplan Meier estimates 57 odds ratios ORs 57 anagrelide 57 concomitant medications 57 Wechsler Memory 57 colesevelam HCl 57 KRAS status 57 TEAEs 57 pulmonary exacerbation 57 alteplase 57 vasomotor 57 postmenopausal osteoporotic women 57 Endothelial dysfunction 57 Cmax 56 platelet inhibition 56 FEV ^ sub 56 clinicopathological 56 cells mcL 56 CD# upregulation 56 acoustic startle 56 linaclotide treated 56 GnRH agonist 56 p = NS 56 CD4 lymphocyte count 56 dalteparin 56 prednisone prednisolone plus 56 nonvertebral fracture 56 plasma HCV RNA 56 PRADAXA #mg 56 CD4 + cell 56 mild renal insufficiency 56 Stent thrombosis 56 antiretroviral naive 56 mRNA expression 56 ABC/3TC 56 flow mediated dilation 56 postop 56 PREZISTA r arm 56 glycaemia 56 APTIVUS r 56 Postoperative 56 coronary stenosis 56 dosage regimens 56 EMBLEM TM 56 AST ALT 56 antiviral efficacy 56 ‰ ¥ 56 placebo PBO 56 RECIST criteria 56 sensitivity specificity 56 urinary excretion 56 adverse cytogenetics 56 mutated KRAS 56 #mg BID [003] 56 ventilatory 56 â ‰ ¥ 56 BARACLUDE r 56 nighttime awakenings 56 non squamous histology 56 hemoglobin A1C 56 #OHD 56 T1 weighted images 56 artery stenosis 56 antidiabetic medications 56 LPV r 56 androgen deprivation 56 autoantibody levels 56 Flu Cy 56 CYP#D# genotype 56 inflammatory biomarkers 56 PANSS Positive 56 aPTT 56 recurrent venous thromboembolism 56 psychopathological symptoms 56 serum sodium levels 56 Functioning GAF 56 QT intervals 56 schizophrenia CIAS 56 TNM staging 56 reduce serum phosphate 56 expiratory flow 56 levodopa therapy 56 serum ALT 56 NYHA 56 Pegasys ® 56 chlorambucil 56 cardiac repolarization 56 intraclass correlation coefficient 56 cytogenetic response 56 AUC0 56 aspirin clopidogrel 56 #.#/#.# mm Hg [001] 56 interferon ribavirin 56 somatic symptom 56 HADS 56 TMC# r 56 aspartate aminotransferase 56 Ki# 56 IOP lowering 56 Celsentri Selzentry 56 juvenile idiopathic arthritis 56 Hb A1c 56 SGPT 56 infarct size 56 hyper IgE syndrome 56 TNF antagonist 56 Likert pain 56 mcg QD 56 antiplatelet therapies 56 plasma cortisol 56 carotid intima media 56 fatty infiltration 56 generalized estimating 56 death reinfarction 56 calculated creatinine clearance 56 MS relapses 56 Hypertrophy 56 pelvic lymphadenectomy 56 TPV r 56 Kaplan Meier curve 56 poor metabolizers 56 mm ³ 56 rhinoconjunctivitis 56 metabolite concentrations 56 hemodynamically unstable 56 Apgar scores 56 Cognitive impairment 56 ER CHOP 56 serum BDNF 56 ß = 56 TNFalpha 56 lispro 56 logistic regression analyzes 56 K ras mutations 56 tirofiban 56 quetiapine XR 56 serum lipid 56 tertiles 56 Sensitivity specificity 56 glycosylated hemoglobin 56 antitumor efficacy 56 receiving ISENTRESS 56 telomere lengths 56 CK # plasma concentrations 56 ziprasidone 56 Poisson regression 56 virological suppression 56 log# 56 chemosensitivity 56 titration phase 56 visilizumab 56 SIMPADICO 56 Thal Dex 56 Lower Limb 56 p# biomarker 56 Lucentis monotherapy 56 #mg/day [002] 56 argatroban 56 μg kg 56 median PFS 56 lymphocyte counts 56 microbiological eradication 56 ventricular tachyarrhythmia 56 orthostatic blood 56 cognitive domains 56 statistical significance p 56 primidone 56 ibandronate 56 CYP#C# genotype 56 mmHg p = 56 antithrombotic therapy 56 peginterferon alfa 2a 56 epoetin alpha 56 bronchopulmonary dysplasia BPD 56 NYHA classification 56 bioprosthetic valve 56 p = #.# [004] 56 idiopathic Parkinson disease 56 akinesia 56 permanently discontinue Vectibix 56 ALT flares 56 thyroglobulin 56 log# reduction 56 mg simvastatin 56 μg liter 56 concurrent ITP 56 beta blocker therapy 56 decitabine 56 Multivariate analyzes 56 hour bronchodilation 56 postinjury 56 adjunctive placebo 56 FluCAM 56 hematopoietic cancers 56 inhaled budesonide 56 immunosuppressive regimen 56 FDG uptake 56 waist circumference WC 56 ALT AST 56 pharmacodynamic effects 56 primary efficacy endpoint 56 logistic regression 56 creatine kinase 56 SSc 56 hippocampal atrophy 56 Depressive symptoms 56 shorter telomere length 56 mycophenolate mofetil 56 aldosterone antagonists 56 oral glucose tolerance 56 TIMP 1 56 antiplatelet medications 56 hours postdose 56 HBV DNA levels 56 Efficacy endpoints 56 Neuropsychological Status 56 ratio WHR 56 #.#mg/dL 56 LANTUS R 56 Sociodemographic 56 isoenzyme 56 tipranavir 56 logMAR 56 highest tertile 56 International Normalized Ratio 56 fasting glucose levels 56 hepatic insulin sensitivity 56 Retreatment 56 bronchial reactivity 56 Cardiotoxicity 56 lumbar spine bone 56 LDH lactate dehydrogenase 56 hyperphenylalaninemia HPA due 56 R# #mg BID 56 autoregulation 56 Univariate analysis 56 Naive Patients 56 ARIXTRA 56 Kaplan Meier 56 HLA DR4 56 APTIVUS R 56 bone microarchitecture 56 urinary albumin excretion 56 variance ANOVA 56 anticholinergic agents 56 x ULN 56 statistically significant p 56 hemodynamic variables 56 Outcome Measures